Dorota M Gertig

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David DL Bowtell, Anne-Marie Mes-Masson, Diane M Provencher, Kurosh Rahimi, Linda E Kelemen, Peter A Fasching, Jennifer A Doherty, Marc T Goodman, Ellen L Goode, Suha Deen, Paul DP Pharoah, et al.

Journal article  |  2021  |  MODERN PATHOLOGY

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimi..

Prognostic gene expression signature for high-grade serous ovarian cancer

J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow, et al.

Journal article  |  2020  |  ANNALS OF ONCOLOGY

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies ..

Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study

Jeffrey HJ Tan, Michael J Malloy, Ramaish Thangamani, Dorota Gertig, Kelly T Drennan, C David Wrede, Marion Saville, Michael Quinn

Journal article  |  2019  |  AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY

BACKGROUND: Adenocarcinoma in situ of cervix is increasingly managed by local excision rather than hysterectomy and this study wil..

BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition

Tania Moujaber, Dariush Etemadmoghadam, Catherine J Kennedy, Yoke-Eng Chiew, Rosemary L Balleine, Catherine Saunders, Gerard Wain, Bo Gao, Russell Hogg, Sivatharsny Srirangan, Casina Kan, Sian Fereday, Nadia Traficante, Ann-Marie Patch, John Pearson, Nicola Waddell, Sean M Grimmond, Alexander Dobrovic, David DL Bowtell, Paul R Harnett, et al.

Journal article  |  2018  |  JCO PRECISION ONCOLOGY

Purpose Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and is characterized by activating mutations in ..

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

Karen Canfell, Michael Caruana, Val Gebski, Jessica Darlington-Brown, Stella Heley, Julia Brotherton, Dorota Gertig, Chloe J Jennett, Annabelle Farnsworth, Jeffrey Tan, C David Wrede, Philip E Castle, Marion Saville

Journal article  |  2017  |  PLOS MEDICINE

BACKGROUND: Using primary human papillomavirus (HPV) testing for cervical screening increases detection of high-grade cervical int..

Time to clinical investigation for Indigenous and non-Indigenous Queensland women after a high grade abnormal Pap smear, 2000-2009

Lisa J Whop, Peter D Baade, Julia ML Brotherton, Karen Canfell, Joan Cunningham, Dorota Gertig, Kamalini Lokuge, Gail Garvey, Suzanne P Moore, Abbey Diaz, Dianne L O'Connell, Patricia Valery, David M Roder, John R Condon

Journal article  |  2017  |  MEDICAL JOURNAL OF AUSTRALIA

OBJECTIVES: To investigate time to follow-up (clinical investigation) for Indigenous and non-Indigenous women in Queensland after ..

Genetic and Environmental Factors in Invasive Cervical Cancer: Design and Methods of a Classical Twin Study

Dorothy A Machalek, John D Wark, Sepehr N Tabrizi, John L Hopper, Minh Bui, Gillian S Dite, Alyssa M Cornall, Marian Pitts, Dorota Gertig, Bircan Erbas, Suzanne M Garland

Journal article  |  2017  |  TWIN RESEARCH AND HUMAN GENETICS

BACKGROUND: Persistent high-risk human papillomavirus (HPV) infection is a necessary prerequisite for development of cervical canc..

Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia

F Sultana, DR English, JA Simpson, KT Drennan, R Mullins, JML Brotherton, CD Wrede, S Heley, M Saville, DM Gertig

Journal article  |  2016  |  INTERNATIONAL JOURNAL OF CANCER

We conducted a randomized controlled trial to determine whether HPV self-sampling increases participation in cervical screening by..

The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011)

Lisa J Whop, Gail Garvey, Peter Baade, Joan Cunningham, Kamalini Lokuge, Julia ML Brotherton, Patricia C Valery, Dianne L O'Connell, Karen Canfell, Abbey Diaz, David Roder, Dorota Gertig, Suzanne P Moore, John R Condon

Journal article  |  2016  |  CANCER

BACKGROUND: The Australian National Cervical Screening Program, introduced more than 20 years ago, does not record the Indigenous ..

Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use

Megan A Smith, Dorota Gertig, Michaela Hall, Kate Simms, Jie-Bin Lew, Michael Malloy, Marion Saville, Karen Canfell

Journal article  |  2016  |  BMC HEALTH SERVICES RESEARCH

BACKGROUND: Following a recent major review of cervical screening, from 2017 Australia will transition from two-yearly cytology-ba..